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Prof Uziel Beller 
Editor in Chief  
International Journal of Gynecological Cancer 
 
Dear Sir, 
Jacobs, Menon et al1, 2 recently reported results of the United Kingdom Collaborative trial of Ovarian 
Cancer Screening (UKCTOCS). The investigators are to be congratulated on successfully undertaking 
and completing such a large complex population-based randomised trial. The only other screening 
trial to report on mortality was the PLCO study,3 which found no mortality benefit and a significantly 
high 15% complication rate from surgical diagnostic evaluation. Several things stand out which 
differentiate UKCTOCS from previous PLCO and Japanese Shizuoka randomised studies.3, 4 These 
include the concept of a longitudinal biomarker algorithm analysis for screening using the Risk of 
Ovarian Cancer algorithm (ROCA), a web-based trial management and call recall system as well as 
tight protocol-driven centralised co-ordination and management.  It is the results of the ROCA driven 
multimodal screening arm which appear particularly encouraging. The authors report a high 
sensitivity of 84%-85.9%, specificity of 99.8%, and an extremely acceptable 2.7 operations per case 
of cancer detected, with a 3% complication rate.1, 2 Although, the Cox model showed a 15% non-
significant mortality benefit, on post-hoc analysis the authors found a potential statistically 
significant delayed effect on mortality >7 years post-randomisation. Their finding of a statistically 
significant stage shift of 14% (40% vs 26%) ≤Stage-3a disease is noteworthy and adds biological 
plausibility to this. This would have resulted in a higher R’0’ resection rate (nil-residual disease) in 
the screened group. R’0’ resection is well documented as the critically important factor associated 
with higher survival rates following debulking surgery for advanced ovarian cancer.5, 6 The 
philosophy of ovarian cancer debulking surgery has changed over the last few years with far more 
complex ultra-radical surgeries being undertaken in most major cancer centres, to achieve ‘nil-
residual’ disease or R’0’ resection. If screening is associated with an increase in lower volume disease 
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this may well lead to the need for proportionally fewer ultra-radical surgical procedures with lower 
morbidity and potentially beneficial cost implications. At the same time, it remains unknown if 
screening also resulted in less bulky or lower volume stage 3b/3c disease which may be more 
amenable to achieving R’0’ resection and better outcomes. This is an important issue and it would 
be helpful if this were further evaluated and reported by the research team. Maximising translation 
of a screening strategy into patient benefit also requires increasing awareness and changing the 
mind set of gynaecological oncologists and multidisciplinary teams to act/operate on a rising 
biomarker without any radiological confirmation of disease. 
This report also highlights for all investigators and trialists the importance of the critical issue of ‘pre-
specified’ analysis and choice of statistical plan. Unlike some other large population based screening 
trials (PLCO3 and National Lung Cancer7 trials), the UKCTOCS pre-specified analysis plan does not 
appear to have taken into account any statistical adjustment for a potential delayed effect on 
mortality. The time needed for the process of diagnosis, treatment, recurrence and occurrence of 
death, can result in a lag/delay between initiation of screening and observation of a mortality 
impact. This has been reported in other screening trials. In such situation mortality rates for the 
screened group relative to those of the control group are not likely to be constant as a function of 
years from randomisation and thus the log-rank test for differences in mortality between the two 
randomised groups is not optimal.8, 9 This leads to a loss in power which may be recovered or 
adjusted for by using other tests that are more sensitive to non-proportional odds alternatives like 
an adaptive weighted log rank test8 or likelihood ratio test9. The trial was underpowered to detect a 
<30% difference that may exist between the arms. The observed stage shift of 14% may well be 
associated with a lower than 30% mortality impact. However, even a lower level of mortality benefit 
could have significant impact on this poor prognostic disease at a population level. This possibility of 
lower volume disease and higher complete cyto-reduction rates translating into a <30% mortality 
benefit may be corroborated by the statistically significant results of the weighted log-rank and 
Royston Palmer tests, which helps boost power of the study to enable identification of a smaller 
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difference between screening and control arms which may exist. The authors have suggested further 
follow-up of the cohort to establish this. 
While many of us hope this will be positive, the possibility that the mortality impact will remain non-
significant despite additional follow-up cannot be discounted.  It is critically important for these 
results to be published and benefits of OC screening well-established to enable appropriate 
inferences before considering introduction into practice/ a national programme. The harms of false 
positive surgery and complications from screening are not insignificant. A negative outcome would 
once again highlight the current limitations of early detection technologies and difficulties linked to 
disease biology. A successful strategy may need to detect tumours 0.4-1.3cm in size and surmount 
the signal-to-noise conundrum associated with this.10 Circulating DNA and multimarker algorithms 
used in a longitudinal analysis may hold promise, but new biomarkers which add significantly to 
Ca125 in the screening context remain to be validated. Novel/innovative functional imaging 
modalities also need to be developed and evaluated. 
We await with interest and hope the results from further follow-up and additional analysis of 
surgical outcomes. 
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